They aren't the only ones. There's a laundry list of companies pushing to trial something.
I may be wrong in my assumption so please correct me if I am. I think the benefit of MPL is that it regulates the mTOR pathway which decreases infectivity and should actually enhance the effectiveness of a drug that would directly treat Covid-19. So to my understanding MPL used in combination with another drug would be the answer.
Ann: PharmAust Shareholder Update, page-127
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.010(4.88%) |
Mkt cap ! $104.6M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.5¢ | 20.5¢ | $244.1K | 1.163M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 71981 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 84173 | 3 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |